DTG/3TC

Phase 3Small molecule

GSK

DTG/3TC is one of 74 small molecule programs targeting Immunodeficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

HIVCompleted

ImmunodeficiencyPhase 3

Active, not recruiting

HIVPhase 3

Completed

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

1 2

Repatha

Amgen

Phase 3

1 3

Prezista

WWim Janssens

Phase 3

2 4

Livalo

MMedicure

Phase 3

1 5

GAMUNEX-C

Grifols Therapeutics LLC

Phase 3

2 6

PCV15

Merck & Co.

Phase 3

1 7

BI201335

Boehringer Ingelheim

Phase 3

1 8

Rosuvastatin and Ezetimibe

Hanmi Pharmaceutical Company Limited

Phase 3

1 9

Emtricitabine/tenofovir )

Merck & Co.

Phase 3

—10

Tenofovir/emtricitabine FDC

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Study completion

NCT06444620

Q4 2028

Post-ApprovalRecruiting

Effectiveness

NCT07031063

Clinical

Trials by Indication[1]

First-line1 trial

Good-first: B/F/TAF As First-line ART

Recruiting·—··NCT06619288·630 enrolled

Immunodeficiency1 trial

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruiting· GSK logo

GSK·Phase 3·NCT05917509·171 enrolled

Effectiveness1 trial

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

Recruiting·IInstituto Mexicano del Seguro Social·Phase 4·NCT07031063·124 enrolled

HIV1 trial

A Phase 3b, Multicenter, Single-arm, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to DTG/3TC Single Tablet Regimen Administered Once Daily From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in People Living With HIV of at Least 50 Years of Age Who Are Virologically Suppressed

Completed· GSK logo

GSK·Phase 3·NCT05911360·205 enrolled

Unspecified1 trial

B/F/TAF to DTG/3TC Switch Study

Active, not recruiting·UUniversity of Nairobi·Phase 3·NCT06444620·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for DTG/3TC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DTG/3TC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DTG/3TC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

DTG/3TC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

First-line1 trial

Immunodeficiency1 trial

Effectiveness1 trial

HIV1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News